Heron Therapeutics, Inc. (NASDAQ:HRTX) will be releasing its earnings data before the market opens on Monday, November 6th. Analysts expect Heron Therapeutics to post earnings of ($0.87) per share for the quarter.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. On average, analysts expect Heron Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Heron Therapeutics, Inc. (HRTX) opened at $16.05 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.72 and a current ratio of 2.82. Heron Therapeutics, Inc. has a 12 month low of $12.21 and a 12 month high of $20.85.
COPYRIGHT VIOLATION WARNING: “Heron Therapeutics, Inc. (HRTX) Set to Announce Earnings on Monday” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.com-unik.info/2017/11/05/heron-therapeutics-inc-hrtx-set-to-announce-earnings-on-monday.html.
Several research firms have recently weighed in on HRTX. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 18th. Jefferies Group LLC reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. BidaskClub downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Northland Securities began coverage on shares of Heron Therapeutics in a research note on Wednesday, September 27th. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Mizuho began coverage on shares of Heron Therapeutics in a research note on Tuesday, September 26th. They issued a “buy” rating and a $28.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $28.36.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics Inc. and related companies.